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Abstract: Chemical modification of pseudo-dimannoside li-
gands guided by fragment-based design allowed for the ex-
ploitation of an ammonium-binding region in the vicinity of
the mannose-binding site of DC-SIGN, leading to the synthe-
sis of a glycomimetic antagonist (compound 16) of unprece-
dented affinity and selectivity against the related lectin lan-
gerin. Here, the computational design of pseudo-dimanno-
side derivatives as DC-SIGN ligands, their synthesis, their
evaluation as DC-SIGN selective antagonists, the biophysical
characterization of the DC-SIGN/16 complex, and the struc-
tural basis for the ligand activity are presented. On the way
to the characterization of this ligand, an unusual bridging in-
teraction within the crystals shed light on the plasticity and
potential secondary binding sites within the DC-SIGN carbo-
hydrate recognition domain.
Introduction
DC-SIGN is a transmembrane C-type lectin expressed at the
surface of dendritic cells. It plays a key role in the recognition
of several pathogens and in the development of various infec-
tions, including Dengue and the HIV virus.[1] Over the past
decade, several glycomimetic ligands have been designed to
act as antagonists of DC-SIGN mediated viral infections by
using as template the pseudo-dimannoside (ps-diMan) scaffold
1 (Figure 1A), composed of a mannose ring connected to a
conformationally locked cyclohexane diol. Chemical modifica-
tions of both the cyclohexane appendages and the 6-position
of mannose, as in 2 and 3, led to improvements in the affinity
of the ligands towards DC-SIGN—which remains modest (from
a 0.9 mm IC50 of 1 in SPR inhibition experiments to 0.3–0.2 mm
for 2 and 3) but can be magnified by their polyvalent presen-
tation.[2] Most importantly, these structural modifications also
led to improved selectivity against the related C-type lectin
langerin, which could be explained by comparative structural
analysis of the two proteins.[3]
In this work, we describe our efforts to improve the affinity
of the pseudo-dimannoside ligands by computational design,
using a fragment-based screening in the X-ray structure of DC-
SIGN carbohydrate recognition domain (CRD) in complex with
1 (PDB 2XR5; PDB=Protein Data Bank). This screening identi-
fied several moieties, predicted to bind to sites adjacent to the
bound pseudo-dimannoside, and potentially amenable to
modify its structures. Among them, we focused on fragments
that favorably interact in the proximity of Phe313. This region,
which is involved in binding several natural oligomannosides,[4]
is near the 2-hydroxyl group of the mannose ring (Man-O2) in
Figure 1. A) The structure of known DC-SIGN antagonists with a pseudo-di-
mannoside core. B) X-ray structure of DC-SIGN/ 1 complex PDB 2XR5: the 2-
hydroxyl group of the mannose ring (Man-O2) points towards the Phe313
side-chain.
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the DC-SIGN/ 1 complex (Figure 1B). Pseudo-dimannoside
structures could be therefore expanded at this position and
could, in principle, engage more productively with the protein,
while remaining easily chemically accessible. The newly de-
signed compounds derived from 1 were predicted to bind in
the DC-SIGN CRD with favorable interactions. As opposed to
screening of non-glycan small molecules, the present approach
takes advantage of a natural sugar element to direct the
ligand to the CRD, thus avoiding off-target effects and interac-
tion with other hot spots of the protein, which have been sug-
gested to allosterically influence glycan binding.[5]
Results and Discussion
Fragment-based virtual screening and ligand design
To locate vicinal pockets as putative additional binding re-
gions, we explored the surrounding of the pseudo-dimanno-
side binding site of DC-SIGN. A virtual screening (VS) of the
Maybridge database (over one thousand drug-like fragments,
www.maybridge.com) was performed by means of Glide using
as starting point the crystallographic structure of DC-SIGN in
complex with 1 (PDB 2XR5). The center of the VS box was
placed at the centroid among residues Phe313, Ser360 and
Lys373, and was expanded by 10 a in each x, y and z axis. A
total of 50 fragments were selected (5% best docked frag-
ments) for visual inspection. Most of the fragments were
placed in the region enclosed by residues Asn344, Glu358,
Ser360, Asn365, Asp367, Phe313, Leu371 and Lys373 (Fig-
ure 2A) and they all bore an ammonium moiety and an aro-
matic ring. The ammonium group was docked into an “ammo-
nium-binding pocket” in close proximity to the Ca2+ binding
site and lined by Phe313, Glu358 and Ser360. Stabilizing inter-
actions thus include ion pair with Glu358 side chain, hydrogen
bond with Ser360 side chain, and cation–p contacts with
Phe313 phenyl ring (Figure 2A). Interestingly, the ammonium-
binding pocket identified by virtual screening corresponds to a
region occupied by highly conserved water molecules in the
known X-ray structures of DC-SIGN and its sugar complexes
(PDB 2IT5, 2IT6, 2XR5, 1SL4 and 1K9I). The aromatic moiety of
the fragments (either a phenyl or a heterocyclic ring) was
found docked close to Phe313, Asn344 and Leu371 side chains
and established p–p or CH–p interactions with these residues.
Other fragments were predicted to bind outside the ammoni-
um-binding pocket, but were not prioritized for further design
and synthesis.
Excitingly, the pose of the fragments docked into the ammo-
nium-binding pocket clearly allowed for conjugation to the po-
sition 2 of the mannose ring of ps-diMan 1, a position with
many opportunities for functionalization not completely ex-
ploited so far. Among the possibilities explored, we focused on
structures that can be easily accessible starting from the 2-
azido derivative of 1 (compound 4 in Scheme 1) and using
Copper(I)-catalyzed Alkyne Azide Cycloaddition (CuAAC) reac-
tion with a-aminoalkynes, to afford the amino triazoles 5
(Scheme 1). Thus, a number of derivatives of general formula 5
were computationally built as putative ligands (including the S
and R configurations; Figures 3 and Figure S1 in the Support-
ing Information) and docked in the DC-SIGN CRD (Figure 2B),
Figure 2. A) Selected superimposed fragments from virtual screening into
the DC-SIGN/1 complex (PDB 2XR5). The red box highlights the ammonium-
binding site and the main residues that flank it. B) Selected newly designed
compounds with general structure 5. Superimposed docked poses into the
average structure of DC-SIGN from MD simulations are shown.
Scheme 1. Putative ligands designed for docking analysis and synthesis.
Figure 3. Triazole derivatives synthesized and tested as DC-SIGN ligands.
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to predict their binding capability. The details of the calcula-
tions are reported in the Supporting Information.
The designed compounds were docked in three different
DC-SIGN conformations: two from the X-ray crystallographic
structures 2XR5 and 2IT5 (differing in some side chains orienta-
tions of the residues close to the carbohydrate binding site,
Figure S2 in the Supporting Information), and a third one ob-
tained as an average from the molecular dynamics (MD) simu-
lation of apo DC-SIGN from PDB 2XR5, in which rotamers of
Val351 were observed. All designed compounds were predict-
ed to bind the CRD mannoside-binding site with the pseudo-
dimannoside moiety bound in similar pose to that of 1 in the
complex with DC-SIGN (PDB 2XR5). The triazole moiety has op-
timal orientation to reach the ammonium-binding pocket and
to allow the ammonium group to interact with Phe313 and
Glu358 side chains (Figure 2B and Figure S3 in the Supporting
Information). On this basis, the synthesis of several triazole de-
rivatives 5 was planned and executed as described below and
selected DC-SIGN/5 complexes were also submitted to MD
simulations (see below).
Synthesis
For the synthesis of the 2-azido pseudo-dimannoside 4, glyco-
syl donor 9 was prepared in three steps starting from d-man-
nosamine hydrochloride 6 (Scheme 2). Compound 6 was con-
verted into the corresponding azide 8 by diazotransfer with
imidazole-1-sulfonyl azide hydrogensulfate 7,[6] as previously
described for GlcNH2 and GalNH2. Applying the same reaction
conditions to ManNH2 6 initially led to poor yields and irrepro-
ducible results. Alternative procedures for the preparation of 2-
deoxy-2-azidoMan derivatives have indeed been reported in
the literature as producing manno-/gluco- mixtures, in which
the gluco-like impurities are often ascribed to contamination of
the mannosamine starting material.[7] We found that formation
of the gluco- by-product (GlcN3) during the diazotransfer is ac-
tually due to epimerization at position 2, promoted by the
excess of potassium carbonate. Stepwise addition of K2CO3 at
low temperature (@20 8C) and careful pH control allow to
avoid epimerization and to obtain reproducible high yields
(90%) of pure 1,3,4,6-tetra-O-acetyl-2-deoxy-2-azidoMan 8,
from which the 2-deoxy-2-azidomannosyl donor 9 was ob-
tained following established protocols.[8]
The known acceptor 10[3a] was glycosylated with 9 in the
presence of a catalytic amount of TMSOTf, affording the de-
sired common intermediate 11 in 90% overall yield. Reaction
of the azide 11 with alkynes through CuAAC[9] followed by
Zempl8n deprotection afforded the triazole derivatives 5 and
12–16 (Scheme 2 and Figure 3), as detailed in the Supporting
Information. The required alkynes were either commercially
available, or prepared in a few steps, as described in the Sup-
porting Information (Figure S7, Supporting Information). The
synthesis of aryl-propargyl amines in enantiomerically pure
form is not trivial.[10] For this preliminary screening we pre-
pared triazole 5d (Figure 3) as an epimeric mixture at the N-
bearing stereocenter by using the corresponding racemic
propargyl amine (commercially available). The two isomers
proved to be chromatographically inseparable, just as the cor-
responding methyl derivatives 5c, and both molecules were
tested as diastereomeric mixtures. On the contrary, the benzyl
alcohols 15b (Figure 3) synthesized as an epimeric mixture
from (:)-1-phenylpropynol could be separated chromato-
graphically and were tested as individual isomers, although
the configuration of the benzylic stereocenter was not as-
signed (15bR/S and 15bS/R in Figure 3). The 2- and 3-pyridyl
derivatives 13 and 14 were synthesized from the correspond-
ing commercially available alkynes.
SPR competition assay
The compounds obtained were tested by surface plasmon res-
onance (SPR) as potential inhibitors of DC-SIGN interaction
with an immobilized mannosylated bovine serum albumin
(BSA). The IC50 values obtained from the SPR inhibition assays
for the triazole derivatives and their parent compounds 1–3
(Figure 1A) are plotted in Figure 4A and the corresponding
values collected in Table S1 (Supporting Information). In bear-
ing with the computational predictions for the ammonium-
binding site, the methylenamino triazole derivative 5a gave an
IC50 of 108:1 mm, with one order of magnitude improvement
over the parent ps-diMan 1. Addition of methyl substituents
on the a carbon of the triazole ring, as in 5b,c was detrimental
for the affinity. Similarly, additional methyl groups on the nitro-
gen atom, meant to stabilize the positive charge as in 12a–c,
led to a significant decrease in affinity. Collectively, these data
suggest a negative effect of steric hindrance at, or near to, the
ammonium-binding site. Interestingly, ligand 15a, in which the
amine is replaced by a hydroxyl group, also provided a three-
fold affinity improvement over 1 (IC50 of 339:7 mm) suggest-
ing a positive role of H-bonding ability in that position.
Indeed, docking of 15a yielded a pose that placed the OH
group into the ammonium-binding site (not shown). This
result is also in agreement with the observation that the am-
monium-binding site identified by VS overlaps with a highly
Scheme 2. Synthesis of the ligands. i) 7, K2CO3, CuSO4*5H2O, MeOH, @20 8C
to R.T. , 4 h; ii) Ac2O, Py, RT, 12 h, 90% over two steps; iii) MeNH2, THF, 0 8C–
R.T. , 5 h, 97%; iv) Cl3CCN, DBU, CH2Cl2, 0 8C, 30 min, 79%; v) 9, TMSOTf,
CH2Cl2, @30 8C, 1 h, 95%; vi) CuSO4·5H2O, Na ascorbate, THF/water; vii) MeO-
Na, MeOH, RT, 30 min.
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conserved hydration site in the DC-SIGN CRD crystals. The
effect of aromatic substituents on the a carbon of the triazole
ring was more difficult to dissect, because the epimeric mix-
ture of a-phenyl derivatives 5d could not be separated. SPR
analysis of the mixture yielded an IC50 of 407:7 mm (Fig-
ure 4A), indicating a fourfold loss of activity relative to 5a.
Luckily, the corresponding epimeric alcohols 15bR/S and
15bS/R could be separated by flash chromatography and
were tested separately in the inhibition experiment, yielding
an IC50 value of 870:1 mm and 590:4 mm, respectively. Thus,
none of the epimers provided an improvement over the
parent alcohol 15a. Alternatively, the 2-pyridyltriazole 13,
which does not feature a positive charge at the pH of the
assay (pH 8), but presents the pyridine nitrogen adjacent to
the triazole ring, afforded an IC50 180:6 mm and, thus, a very
significant improvement over 1. This suggests that the pyridine
moiety can be engaged in stabilizing (lipophilic) contacts with
the protein surface. Docking calculations predict the pyridine
ring to be involved in edge-to-face interactions with the
Phe313 side chain and possibly in H-bonding interaction with
Lys373. Indeed, the position of the pyridine nitrogen appears
to play a crucial role, since the 3-pyridyl derivative 14, with an
IC50 609:6 mm, shows a fivefold loss of activity relative to 13.
Overall, functionalization of the mannose residue with a tri-
azole ring carrying an ammonium group was found to increase
the DC-SIGN affinity, as expected based on the computational
models. So far, the beneficial effects of an aromatic substituent
have not been fully confirmed by the limited set of com-
pounds synthesized and analyzed.
Based on the SPR results, 5a was chosen as lead compound
for transformation into 16 (Figure 3), which combines the
backbone structure of 2 (carrying two p-hydroxymethylene-
benzylamide substituents on the cyclohexane ring) and the
functionalization of 5a at mannose C-2. As mentioned above,
2 has an enhanced affinity towards DC-SIGN compared to 1
(IC50=329 mm and 956 mm for 2 and 1, respectively) and is sig-
nificantly more selective against langerin.[3a] Thus, this switch
of scaffold was expected to improve both affinity and selectivi-
ty of the ammonium-carrying ligand. SPR binding inhibition
studies were performed for 16 and DC-SIGN affording an IC50
of 76:3 mm (Figure 4A). Additionally, 5a, 13 and 16 were also
tested against langerin: selectivity towards DC-SIGN increased
from 5a to 13 and reached a maximum with 16 (Figure 4B).
Thus, 16 is the most effective and selective mannose-based
glycomimetic antagonist developed to date against DC-SIGN.
Biophysical characterization of 16 binding to DC-SIGN
To further characterize the binding interaction of 16 with DC-
SIGN, an ITC titration was performed. Ligand 16 (2.5 mm) was
titrated into a DC-SIGN solution (100 mm) (Figure S5A, Support-
ing Information). A one binding site model fitting of the data
with an assumed stoichiometry value fixed to 1 yielded an
equilibrium dissociation constant KD of 52.0:1.3 mm, in agree-
ment with the IC50 determined by competition assay (IC50 76:
3 mm). The high affinity of 16 for DC-SIGN also allowed for the
evaluation of the interaction in a SPR direct binding mode by
using a DC-SIGN functionalized surface.[11] The resulting KDapp
from steady state fitting was found to be 52.7:2.7 mm (Fig-
ure S5B, Supporting Information) in good agreement with the
results obtained by ITC. The ITC analysis yielded DH=@19.6:
0.2 kJmol@1 and a TDS=4.9:0.2 kJmol@1, leading to a DG of
@24.46 kJmol@1. Thus, 16 binding is mainly enthalpically
driven, potentially due to the additional interactions brought
by the amino group added in 16.
X-ray crystallography
Co-crystallization experiments of DC-SIGN CRD and 16 were
conducted. Crystals were obtained and their structure was
solved at 2.1 a resolution (PDB 6GHV). The data revealed a to-
tally new crystal packing, compared to previous DC-SIGN struc-
tures, with an asymmetric unit composed of six CRDs and six
molecules of 16 (Figure 5A). This crystal packing (space group
P1211) is enabled by each ligand molecule reaching out to a
second CRD unit, thus forming a symmetric network (Fig-
Figure 4. A) IC50 of triazoles derivatives towards DC-SIGN (corresponding numerical values in Table S1); B) SPR inhibition assay for 5a (green), 13 (red) and 16
(blue). Inhibition curves of DC-SIGN (circle) and langerin (square) binding to a mannosylated surface are shown.
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ure 5C). Each ligand therefore bridges the canonical Ca2+ bind-
ing site in one CRD and a cavity generated between helix 2
and the following loop upstream of the b4 strand of the next
CRD (Figure 5C). As expected, the Ca2+ ion is coordinated by
Man-O3 and Man-O4, while the noncanonical site in the next
CRD is occupied by one of the p-hydroxymethylenebenzyl-
amide substituents of 16. In addition to these two main inter-
actions sites, 16 is also in contact with a neighboring third
CRD (the green chain in Figure 5B), thanks to the second
benzylamide arm. The binding mode of 16, due to the extend-
ed interaction with DC-SIGN CRDs in this packing, is very well
defined, allowing a fine analysis within each different binding
site (Figure 5B,C as well as Figures 6 and 7). Compared to the
X-ray structure of DC-SIGN/ 1 complex, the two additional frag-
ments of 16 that make contact with the protein, both the am-
monium group and the intercalated benzylamide arm, point to
druggable secondary sites recently identified by Aretz et al.[12]
(Figure S6, Supporting Information).
The noncanonical interaction site that determines the bridge
between CRDs by 16 in the crystals is shown in Figure 6. The
overlay of the backbone structures of DC-SIGN CRD (PDB 1K9I,
Figure 6, pink) with the structure of our complex (Figure 6,
cyano) shows a conservation of structural elements, with the
exception of a kink in helix 2. This helix movement results from
the insertion of a p-hydroxymethylenebenzylamide arm be-
tween the helix and a facing loop (Figure 6). Backbone CO
group from Ser271 provides stabilizing H-bond with the ben-
zylic hydroxy group of 16 through a bridging water molecule
(Figure 6A), whereas a large movement of Arg312 generates
the required cavity (compare Figure 6B and C) and provides
additional stabilization through H-bond with the amide car-
bonyl (Figure 6A). These structural adjustments for the p-hy-
droxymethylenebenzylamide arm illustrate the plasticity of the
CRD backbone of DC-SIGN as previously observed for langer-
in.[13]
In the crystal, 16 interacts similarly to the previously charac-
terized binding mode for the glycomimetics 1–3[3, 14] exploiting
Val351 side chain for nonpolar interactions with the cyclohex-
ane ring. Here, for the first time, details of the interaction of
the benzylamide arm with the primary CRD surface, previously
suggested by NMR studies, are highlighted. Thus, the amide
carbonyl is H-bonded to Lys368 in the CRD, the benzyl ring is
in van der Waals contact with the loop containing Val351 and
Gly352 and the terminal OH group is involved in a H-bonding
network with the protein surface through two water molecules
(Figure 7A). These results are in agreement with MD calcula-
tions of the complex, which anticipated one of the benzyl-
amide arms to be dangling in the solvent (thus becoming
available for the secondary interactions described above) and
the second one oscillating CH–p interactions with Val351 and
Gly352, whereas its terminal hydroxyl group alternates H-
bonds with the backbone CO of Asn350, Gly352 NH and sol-
vent water molecules (Figure 7C and Figure S4 in the Support-
ing Information). The additional ammonium group, connected
to mannose C-2 through a triazole linker, reaches Ser360 and
Glu358, as initially predicted from the docking analysis. Inter-
Figure 5. Crystallization packing dependence on 16. A) Crystal packing
within crystals of the DC-SIGN CRD/16 complex, dark square is zoomed in
B). B) Omit map of 16 highlighting its position at the interface of three CRD
units. The majority of interactions occur with two of the CRDs (cyan and
orange chains). C) Symmetrical dimer of CRDs bridged by two molecules of
16. Both ligands are bound to one of the CRDs through the canonical Ca2+
ion site and establish an additional interaction with a second CRD, involving
one benzylamide arm of 16 and a cavity between helix 2 and the loop up-
stream of the CRD ß5 strand. Pink spheres are Ca2+ ions, green spheres are
chloride ions.
Figure 6. Non-canonical binding site of 16. A) Overlay of DC-SIGN CRD X-ray
structure (pink, PDB 1K9I) and DC-SIGN CRD co-crystallized with 16 (cyan,
PDB 6GHV) highlighting the kink of helix-2 due to insertion of the p-hy-
droxymethylenebenzylamide fragment. A second copy of 16 in its canonical
Ca2+ binding site can be seen in the back of the Figure, where the Ca2+ ion
is shown in magenta. B) and C) The comparison between the two CRDs
shows the cavity generated by Arg312 movement (see in A).
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estingly, also the MD simulations of DC-SIGN/16 described a
stable complex, with the ammonium group interacting with
Phe313 and Glu358 side chains during the entire simulation
time (100 ns, Figure S4, Supporting Information). In this posi-
tion, a cation–p interaction is also generated with Phe313, as
expected from the distance of 3.3 a between the ammonium
group and the phenyl ring (Figure 7A). The cumulative interac-
tions resulting from the ammonium ion may account for the
improved enthalpy contribution to the binding observed in
the ITC studies described above. In Figure 7B, the CRD repre-
sentation as electrostatic surface potential highlights the nega-
tive potential favoring ammonium binding.
Due to the peculiar position of 16 at the interface of three
CRDs in the crystal packing, the relevance of the binding
mode observed in the Ca2+ binding site could be questioned.
However, the conservation of the binding mode observed with
1 and 2, from which 16 is derived, and the perfect correlation
of the ammonium group binding pocket with the computa-
tional prediction support the coherence of the complex struc-
ture observed. The question remains whether the unexpected
bridging interaction observed in the crystal may also be pres-
ent in solution and account for the improved affinity of 16 for
DC-SIGN. Bridging of DC-SIGN tetramers by glycomimetic li-
gands in solution has been previously observed and character-
ized by analytical ultracentrifugation (AUC) with a pseudo-tri-
mannoside compound.[15] Thus, to discriminate between a crys-
tallization-induced artefact and a genuine additional binding
site in solution, AUC experiments were performed by using
either DC-SIGN CRD (Figure 8A, crystallization condition) or the
full tetrameric extracellular domain (ECD, Figure 8B) at fixed
concentration (56 and 26 mm, respectively), while increasing
Figure 7. A) Binding mode of 16 in the canonical Ca2+ binding site of DC-
SIGN (PDB 6GHV). H bonds are represented in yellow, van der Waals and
cation–p interactions with Phe313 in green. Ca2+ ions are represented as
magenta sphere. B) The same complex. View rotated by 1808 and protein
represented as electrostatic surface. C) 3D Structure of DC-SIGN (cyan) in
complex with compound 16 (blue) from MD simulation. Superimposed crys-
tallographic (yellow, PDB 6GHV) and docked (magenta) poses of compound
16 are depicted.
Figure 8. AUC analysis of A) DC-SIGN CRD/16 complex and B) DC-SIGN ECD/
16 complex in solution.
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the concentration of 16. For the CRD, the sedimentation coeffi-
cient remained unchanged to a value around 1.8 S (s20w=
2.1 S), at all the used concentrations of 16, showing the ab-
sence of dimerization and, therefore, the absence of a cluster-
ing effect of 16 towards DC-SIGN CRD in solution, as opposed
to the crystal context. The same was found for DC-SIGN ECD,
which sedimented as a tetramer at 4.5 S (s20w=5.4 S, close to
the previously published), alone and in the presence of 16.[15,16]
From this last characterization, we can assume that only bind-
ing in the canonical Ca2+ site exists in solution and is by itself
responsible for the unprecedented affinity observed with this
glycomimetic.
Conclusion
In summary, chemical modification of the known glycomimetic
ligand 1 guided by fragment-based design allowed for the ex-
ploitation of an ammonium-binding region in the vicinity of
the sugar-binding site of DC-SIGN, improving by one order of
magnitude the inhibitory potency. ITC confirmed that the
novel antagonist 16, with a KD of 52:1 mm, is among the
most potent monovalent DC-SIGN ligands so far described,[17]
whereas SPR analysis showed that it is also fully selective for
DC-SIGN versus langerin. The X-ray structure of the DC-SIGN/
16 complex fully validated the modeling prediction and of-
fered a structural basis for the result interpretation. In particu-
lar, the presence of an ammonium ion in 16 contributes simul-
taneously to the high affinity for DC-SIGN, by interacting with
an ammonium-binding region in the vicinity of Phe313, and to
the selectivity for DC-SIGN vs. langerin, which harbors a largely
positive binding site rich in lysine residues.[3b] AUC analysis
convincingly confirmed that the affinity increase observed for
16 relative to previous pseudo-dimannoside-type ligands is
not due to induced aggregation of soluble DC-SIGN CRD. Alto-
gether, these features make 16, originated from a fragment-
based design approach, the best glycomimetic developed to
date to efficiently target DC-SIGN. In addition, the intriguing
features observed in the X-ray structure of the DC-SIGN/16
complex offer a glimpse of the plasticity of the receptor CRD,
which is likely to be central to a full understanding of its ma-
chinery.
Experimental Section
Computational methods
Virtual screening was performed by using Glide and the Maybridge
Ro3 core set fragment library. Ligand docking was performed by
using AutoDock 4 and the MD simulations using AMBER14. The ex-
perimental details are reported in the Supporting Information.
Syntheses
General experimental conditions are reported in the Supporting in-
formation. 3-Azidosulfonyl-3H-imidazol-1-ium hydrogen sulfate 7
was synthesized as described in Ref. [6b]. The alkynes used for the
CuAAC reactions are collected in Figure S7 (Supporting Informa-
tion). The synthesis of the non-commercially available alkynes and
the full synthesis of 16 are described in the Supporting informa-
tion.
1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-d-mannopyranose (8): d-
Mannosamine hydrochloride (1.2050 g, 5.59 mmol, 1 molequiv)
was suspended in dry MeOH (50 mL) and cooled to @20 8C. K2CO3
(811 mg, 5.87 mmol, 1.05 mol equiv) was dissolved in 4 mL water
and added to the stirred suspension. CuSO4*5H2O (14 mg,
0.06 mmol, 0.01 molequiv) was added to the mixture. Another por-
tion of K2CO3 (811 mg, 5.87 mmol, 1.05 molequiv) in 4 mL water
was added, immediately followed by the addition of imidazole-1-
sulfonyl azide (1.8190 g, 6.7080 mmol, 1.2 molequiv). The pH was
continuously controlled and the reaction was stirred at @20 8C for
2 hours, when it was left to warm to RT (light-blue suspension).
After 4 hours, only one major spot was detected by TLC (Rf=0.4 in
8:2 CH2Cl2/MeOH). The solvent was evaporated in vacuo and the
crude was suspended in dry pyridine (20 mL). The mixture was
cooled to 0 8C and Ac2O (4.22 mL, 44.72 mmol, 8 molequiv) was
added dropwise. The reaction was stirred overnight at RT and the
next day only one major spot was detected on TLC (Rf=0.36 in tol-
uene/EtOAc=9:1). The crude was purified by flash chromatogra-
phy (toluene/EtOAc=9:1) to yield the pure product 8 as a white
foam (1.9 g, 92%), a/b=2:1. a-anomer: 1H NMR (400 MHz, CDCl3):
d=6.09 (d, 1H, H1, J1-2=1.9 Hz), 5.43–5.34 (m, 2H, H3, H4), 4.21 (dd,
1H, H6a, J=4.6 Hz, J=12.4 Hz), 4.08 (dd, 1H, H6b, J=2.2 Hz, J=
12.4 Hz), 4.04–3.98 (m, 2H, H2, H5), 2.16 (s, 3H, AcO), 2.11 (s, 3H,
AcO), 2.09 (s, 3H, AcO), 2.05 ppm (s, 3H, AcO); 13C NMR (100 MHz,
CDCl3): d=170.6 (C=O (AcO)) ; 169.9 (C=O (AcO)) ; 169.3 (C=O
(AcO)) ; 168.1 (C=O (AcO)); 91.7 (C1) ; 71.1 (C3) ; 71.1 (C5) ; 65.6 (C4) ;
62.1 (C6) ; 60.1 (H2) ; 21.2 (Me (OAc)) ; 20.9 (Me (OAc)); 20.9 (Me
(OAc)) ; 20.8 ppm (Me (OAc)).
b-anomer: d=5.81 (d, 1H, H1, J1-2=1.4 Hz), 5.27 (t, 1H, H4), 5.04
(dd, 1H, H3, J=3.7 Hz, J=9.8 Hz), 4.23 (dd, 1H, H6a, J=4.9 Hz, J=
12.4 Hz), 4.06 (dd, 1H, H6b, J=2.4 Hz, J=12.4 Hz), 4.04–3.98 (m, 1H,
H2), 3.70 (ddd, 1H, H5, J=2.4 Hz, J=4.9 Hz, J=9.9 Hz), 2.18 (s, 3H,
AcO), 2.11 (s, 3H, AcO), 2.08 (s, 3H, AcO), 2.04 ppm (s, 3H, AcO).
13C NMR (100 MHz, CDCl3): d=170.6 (C=O (AcO)) ; 169.9 (C=O
(AcO)) ; 169.3 (C=O (AcO)) ; 168.1 (C=O (AcO)); 91.5 (C1) ; 73.6 (C5) ;
72.2 (C3) ; 65.3 (C4) ; 62.1 (C6) ; 61.4 (H2) ; 21.1 (Me (OAc)) ; 21.1 (Me
(OAc)) ; 21.0 (Me (OAc)); 20.9 ppm (Me (OAc)).
3,4,6-Tri-O-acetyl-2-azido-2-deoxy-d-mannopyranose. 1,3,4,6-
tetra-O-acetyl-2-azido-2-deoxy-D-mannopyranose 8 (506 mg,
1.36 mmol, 1 mol equiv) was dissolved in 1 mL dry THF and cooled
to 0 8C. 813 mL 2m MeNH2 in THF (1.63 mmol, 1.2 mol equiv) was
added to the solution and the reaction was stirred at RT for
1.5 hours. After completion, the mixture was concentrated and the
crude was purified by flash chromatography (Rf : 0.27 (a) and 0.24
(b) in toluene/EtOAc=6:4). The product was obtained in 97% yield
(437 mg) as a 87:13 a : b anomeric mixture. 1H NMR (400 MHz,
CDCl3): a-anomer: d=5.45 (dd, 1H, H3, J2-3=3.8 Hz, J3-4=9.8 Hz),
5.35 (t, 1H, H4, J4-5=9.5 Hz), 5.27 (s, 1H, H1), 4.26–4.09 (m, 3H, H6a,b,
H5), 4.06 (dd, 1H, H2, J1-2=1.8 Hz), 2.10 (s, 3H, OAc), 2.09 (s, 3H,
OAc), 2.05 (s, 3H, OAc). b-anomer: d=5.29–5.23 (m, 1H, H4), 5.13
(dd, 1H, H3, J2-3=3.8 Hz, J2-3=9.9 Hz), 4.91 (d, 1H, H1, J1-2=6.4 Hz),
4.26–4.10 (m, 2H, H6a,b), 3.67–3.60 (m, 2H, H5, H2), 2.12 (s, 3H, OAc),
2.10 (s, 3H, OAc), 2.05 ppm (s, 3H, OAc); 13C NMR (100 MHz, CDCl3):
a-anomer: d=170.8 (C=O (AcO)) ; 170.0 (C=O (AcO)); 169.6 (C=O
(AcO)) ; 92.8 (C1) ; 70.7 (C3) ; 68.6 (C5) ; 65.9 (C4) ; 62.2 (C6) ; 61.7 (C2) ;
20.8 (Me (OAc)); 20.7 (Me (OAc)) ; 20.6 (Me (OAc)). b-anomer: d=
170.8 (C=O (AcO)); 170.0 (C=O (AcO)); 169.6 (C=O (AcO)); 92.7 (C1) ;
72.8 (C3) ; 72.4 (C5) ; 65.4 (C4) ; 63.5 (C2) ; 62.1 (C6) ; 20.8 (Me (OAc));
20.7 (Me (OAc)) ; 20.6 ppm (Me (OAc)) ; MS (ESI): m/z calculated for
[C12H17N3O8Na]
+ : 354.1 [M+Na]+ ; found: 354.1.
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2-Azido-2-deoxy-3,4,6-tri-O-acetyl-d-mannose trichloroacet-
imidate (9): 3,4,6-tri-O-acetyl-2-azido-2-deoxy-d-mannopyranose
(400 mg, 1.20 mmol, 1 mol equiv) was dissolved in 5 mL CH2Cl2,
cooled to 0 8C and trichloroacetonitrile (1.33 mL, 13.29 mmol,
11 mol equiv) was added to the solution. Then, 1,8-diazabicy-
clo[5.4.0]undec-7-ene (DBU; 45 mL, 0.30 mmol, 0.25 molequiv) was
added and the reaction was stirred at RT under N2 overnight. After
completion, the mixture was concentrated and the crude was puri-
fied by flash chromatography (Rf : 0.38 in hexane/EtOAc=75:25) to
yield the pure product as a white foam (439 mg, 77% yield, exclu-
sively a-product). [a]20D : +88.98 (c=0.6 in CH2Cl2).
1H NMR
(400 MHz, CDCl3): d=8.77 (s, 1H, NH), 6.29 (d, 1H, H1, J1-2=1.8 Hz),
5.45 (t, 1H, H4, J4-3= J4-5=10.0 Hz), 5.43 (m, 1H, H3), 4.28 (dd, 1H,
H2, J2-3=3.3 Hz), 4.25 (dd, 1H, H6a, J6a-6b=12.7 Hz, J6a-5=4.8 Hz,),
4.18–4.12 (m, 2H, H5, H6b), 2.12 (s, 3H, OAc), 2.09 (s, 3H, OAc),
2.07 ppm (s, 3H, OAc); 13C NMR (100 MHz, CDCl3): d=170.8 (C=O
(AcO)) ; 170.1 (C=O (AcO)) ; 169.6 (C=O (AcO)) ; 160.0 (C=NH); 95.5
(C1) ; 90.42 (CCl3) ; 71.4 (C5) ; 70.8 (C3) ; 65.2 (C4) ; 61.8 (C6) ; 60.0 (C2) ;
20.9 (OAc); 20.8 (OAc); 20.7 ppm (OAc); MS (ESI): m/z calculated for
[C14H17Cl3N4O8Na]
+ : 497.01 [M+Na]+ ; found: 496.88.
1,2-Cyclohexanedicarboxylic acid, 4-(2-chloroethoxy)-5-((3,4,6-O-
triacetyl)-2-azido-a-d-2-deoxymannopyranosyloxy)-1,2-di-
methylester (1S,2S,4S,5S) (11): A mixture of the acceptor 10[3a]
(124 mg, 0.42 mmol, 1 mol equiv) and the donor 9 (200 mg,
0.42 mmol, 1 molequiv) was co-evaporated with toluene three
times. Powdered and activated 4 a molecular sieves (acid washed)
were added. The mixture was kept under vacuum for 3–4 hours
and then dissolved in dry CH2Cl2 (10 mL). After cooling to @30 8C,
trimethylsilyl trifluoromethanesulfonate (TMSOTf; 15.2 mL,
0.084 mmol, 0.2 mol equiv) was added to the stirred mixture. The
solution was stirred at @30 8C for 1 hour and upon completion, the
reaction was quenched with triethylamine (TEA). The mixture was
warmed to room temperature and filtered over a Celite pad. The
filtrate was evaporated at reduced pressure and the crude product
was purified by flash chromatography (hexane/EtOAc=72:28) to
yield the pure product as a white foam (240 mg, 94% yield, exclu-
sively a-product). [a]20D : +73.48 (c=0.68 in CH2Cl2) ;
1H NMR
(400 MHz, CDCl3): d=5.35 (dd, 1H, H3, J3-2=3.6 Hz, J3-4=9.6 Hz),
5.29 (dd, 1H, H4, J4-5 = 9.4 Hz), 4.98 (d, 1H, H1, J1-2 = 1.5 Hz), 4.21
(dd, 1H, H6a, J6-5 = 5.4 Hz, J6-6b = 12.2 Hz), 4.08 (dd, 1H, H6b, J6b-5=
2.3 Hz), 4.03 (m, 1H, H2), 3.98–3.94 (m, 1H, H5), 3.94–3.90 (m, 1H,
C2), 3.87–3.80 (m, 1H, H7a), 3.70 (s, 3H, H10), 3.69 (s, 3H, H10), 3.68–
3.64 (m, 1H, H7b), 3.62–3.59 (m, 2H, H8a,b), 3.59–3.58 (m, 1H, C1),
3.02 (dt, 1H, C4, JC4-C3eq=4.0 Hz, JC4-C3ax= JC4-C5=12.0 Hz), 2.88 (dt,
1H, HC5, JC5-C6eq = 4.0 Hz, JC5-C6ax =12.0 Hz), 2.10 (s, 3H, OAc), 2.08
(s, 3H, OAc), 2.04 (s, 3H, OAc), 2.10–1.80 ppm (m, 4H, HC3ax, HC3eq,
HC6eq, HC6ax) ;
13C NMR (100 MHz, CDCl3): d=174.9 (C9) ; 174.6 (C9) ;
170.8 (C=O (AcO)); 170.0 (C=O (AcO)); 169.6 (C=O (AcO)); 95.9 (C1) ;
75.3 (CC1) ; 71.7 (CC2) ; 71.0 (C3) ; 69.6 (C7) ; 69.2 (C5) ; 66.3 (C4) ; 62.6
(C6) ; 61.9 (C2) ; 52.2 (C10) ; 43.2 (C8) ; 39.2 (CC5) ; 39.0 (CC4) ; 28.0, 26.8
(CC3, CC6) ; 20.9 (Me (AcO)) ; 20.8 (Me (AcO)) ; 20.7 ppm (Me (AcO)) ;
MS (ESI): m/z calculated for [C24H34ClN3O13Na]
+ : 630.17 [M+Na]+ ,
found: 630.51
General procedure for CuAAC reactions. 1m CuSO4·5H2O and Na
ascorbate solutions were prepared in degassed water. The alkyne
(1 molequiv) was dissolved in degassed THF and 0.1 equiv
CuSO4·5H2O solution and 0.4 molequiv Na ascorbate solutions
were added, under nitrogen atmosphere. The azide was also dis-
solved in degassed THF and added to the mixture. The reaction
was stirred under nitrogen, then, upon completion, QuadraSilTM MP
metal scavenger was added to remove the copper, the mixture
was filtered and concentrated in vacuo. When the purity of the
protected product was satisfactory, the crude was used directly in
the following Zempl8n-deprotection step.
General procedure for Zempl8n deacetylation : 1 mol equiv
acetylated compound was dissolved in distilled MeOH and 1m
freshly prepared NaOMe in MeOH was added to the solution
(1.5 mol equiv NaOMe) to 0.1m final concentration of the sub-
strate. After completion, the reaction was neutralized with Amber-
liteS IR120 hydrogen form ion-exchange resin, filtered and concen-
trated in vacuo. The crude was purified by direct (CH2Cl2/MeOH) or
reversed-phase flash chromatography (water/MeOH/MeCN, for am-
monium salts 0.01% TFA was added), yielding the pure product.
Compounds 5a–c, 12a–c and 16 were isolated as ammonium tri-
fluoroacetate salts.
Compound 16 : Obtained in 76% yield over two steps (CuAAC and
deacetylation). Rf : 0.38 in water/MeOH=1:1 +0.01% TFA.
1H NMR
(400 MHz, CD3OD): d=8.29 (s, 1H, HTrCH), 7.30–7.18 (m, 8H, H12,
H13), 5.28 (s, 1H, H1), 5.22 (dd, 1H, H2, J1-2=1.0 Hz, J2-3=5.1 Hz),
4.55 (d, 4H, H10, J=2.6 Hz), 4.32–4.20 (m, 7H, H3, H15, H16), 4.12–
4.08 (m, 1H, C2), 3.92–3.82 (m, 3H, H6a,b, H7a), 3.79–3.72 (m, 3H, H5,
H7b, C1), 3.69–3.60 (m, 3H, H8a,b, H4), 3.01–2.83 (m, 2H, C4, C5), 2.03–
1.89 ppm (m, 4H, C3, C6) ;
13C NMR (100 MHz, D2O): d=177.9 (C9) ;
177.6 (C9) ; 142.5, 142.4 (C14) ; 140.7 (CTrq) ; 139.8 (C11) ; 129.3 (C13) ;
129.2 (C12) ; 126.8 (CTrCH) ; 98.3 (C1) ; 77.1 (CC1 or C5) ; 76.7 (C5 or CC1) ;
73.2 (CC2) ; 71.6 (C7) ; 71.1 (C3) ; 69.0 (C4) ; 65.8 (C10) ; 65.5 (C2) ; 63.0
(C6) ; 45.2 (C8) ; 44.6, 44.5 (C15) ; 42.5 (CC4, CC5) ; 36.3 (C16) ; 30.8,
29.3 ppm (CC3, CC6). MS (HRMS): m/z calculated for [C35H48ClN6O10]
+ :
747.3120 [M+H]+ , found: 747.3123.
Sample preparation for ITC
ITC experiments were performed at 25 8C by using a TA Instrument
Nano Isothermal Titration Calorimeter Low Volume (Nano ITC LV)
with a 190 mL cell volume. Compound 16 and DC-SIGN ECD were
prepared in 25 mm Tris-HCl at pH 8, 150 mm NaCl, 4 mm CaCl2 and
4% DMSO. 100 mm of DC-SIGN ECD and 2.5 mm compound con-
centrations were used. The compound was stepwise injected
(1.03 mL) into DC-SIGN solution by using 5 min intervals between
injections. A blank titration (compound to buffer) was done for
subtraction of dilution heat from the integrated data. A one-site
binding model was fitted to the data (nanoAnalyse 2.20 TA), yield-
ing dissociation constants (KD) and binding enthalpies (DH).
Surface plasmon resonance (SPR) analysis
The extracellular domain (ECD) of DC-SIGN (residues 66–404) was
overexpressed and purified as previously described. The SPR ex-
periments were performed on a BIAcore T200 using a CM3 sensor
chip. Flow cells were activated as previously described.[18] Flow cell
one was functionalized with BSA and blocked with ethanolamine
and subsequently used as a control surface. Flow cells 2 and 3
were treated with BSA-Mana1-3[Mana1-6]Man (Dextra)
(60 mgmL@1) in 10 mm NaOAc pH 4 to reach different binding den-
sities and blocked with ethanolamine. The final densities on flow
cells 2 and 3 were 2579 and 2923 RU, respectively. The affinity of
the various compounds for DC-SIGN ECD were evaluated via an es-
tablished inhibition assay[18] in which DC-SIGN ECD was injected at
20 mm alone or in the presence of increasing concentration of in-
hibitors (ranging from 0 to 5 mm). Injections were performed at
5 mLmin@1 using 25 mm Tris-HCl pH 8, 150 mm NaCl, 4 mm CaCl2,
0,05% P20 surfactant as running buffer. The surface was regenerat-
ed by the injection of 50 mm EDTA.
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Crystallization and X-ray data collection
HTX crystallization platform (EMBL) was used to screen conditions
of co-crystallization with the hanging-drop vapor-diffusion method
at 293 K. The drop was composed of a protein/reservoir ratio of
1:1 with protein concentrated at 5.54 mgmL@1 in 150 mm NaCl,
4 mm CaCl2, 25 mm Tris-HCl pH 8, 2% (v/v) DMSO buffer and
3.25 mm 16. Among the crystallization hits obtained, the condition
F04 (200 mm Mg(NO3)2, 20% PEG 3350) from the kit PEGs-Suite
Qiagen was chosen for manual optimization screening with four
different buffers (MES pH 6, HEPES pH 7, Tris pH 8 and Bicine pH 9),
concentration of PEG 3350 (15%-25%) and Mg(NO3)2 concentration
(from 150 to 200 mm). Finally, the best crystals were obtained in
the following condition: 20% PEG 3350, 200 mm Mg(NO3)2,
100 mm MES pH 6.
Crystals were directly flash frozen in liquid nitrogen using Para-
tone-N as cryoprotectant. Data collection was performed at id30A-
1 beamline (MASSIF-1), ESRF Grenoble, 3200 images were collected
at 1008K, with an oscillation range of 0.058, an exposure time of
0.039 s per image, and a wavelength of 0.966 a. Data processing
and refinement statistics are described in Table S2 (Supporting In-
formation). Coordinates and associated structure factors have been
deposited in the PDB database, code: 6GHV.
Analytical ultracentrifugation
Sedimentation velocity experiments were performed in a Beckman
XL-I analytical ultracentrifuge with a rotor Anti-50 (Beckman Coult-
er, Palo Alto, USA) and double-sector cells of optical path length 3
and 1.5 mm equipped of Sapphire windows (Nanolytics, Potsdam,
DE). Samples were centrifuged at 42000 rpm (130000 g), at 20 8C.
Sedimentation velocity profiles were acquired at 280 nm, every
10 min, with a 30 mm radial step size. DC-SIGN CRD or ECD con-
centration was fixed at 1.0 mgmL@1 (56 and 26 mm, respectively),
and compound 16 was used at variable concentration of 0, 15.6,
31.25, 62.5, 125, 250, and 500 mm. Solvent was 25 mm Tris-HCl pH8,
150 mm NaCl, 4 mm CaCl2, 4 mm DMSO (density 1.0055 gmL
@1 and
viscosity 1.0235 cp, estimated, neglecting DMSO, using the SEDN-
TERP software (available free at http://sednterp.unh.edu/). The par-
tial specific volume (v¯) for DC-SIGN CRD and DC-SIGN ECD, was es-
timated from the amino acid compositions as 0.712, and
0.731 mLg@1, respectively, and their molar mass (M) as 17.7 and
38.8 kDa, by using the SEDFIT software (available free at https://
sedfitsedphat.nibib.nih.gov). Data were analyzed in terms of con-
tinuous size distribution c(s) of sedimentation coefficients, s,[19] by
using SEDFIT. Peak integration and figures were done with the
GUSSI software[20] (http://biophysics.swmed.edu/MBR/softwar-
e.html). The s and M values were combined in the Svedberg equa-
tion to calculate the hydrodynamic radius, RH, or frictional ratio fmin
(f/fmin=RH/Rmin, with Rmin the radius of the anhydrous volume)
[Eq. (1)]:
for DC-SIGN CRD considered as a monomer, f/fmin=1.4 is derived
from the experimental s=1.8 S, which corresponds to a moderate-
ly anisotropic shape.[21] The Svedberg equation was also used to
derive corrected in water and at 20 8C s20w values.
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